---
title: KCNA2 IgG autoimmunity in neuropsychiatric diseases
date: '2024-02-03'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38309639/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240204170643&v=2.18.0
source: heidelberg[Affiliation]
description: 'CONCLUSION: Our data suggest that KCNA2 autoimmunity is clinically heterogeneous.
  Future studies should determine whether KCNA2 autoantibodies are directly pathogenic
  or develop secondarily. Early immunotherapy should be considered, in particular
  if autoantibodies occur in CSF or if clinical or diagnostic findings suggest ongoing
  inflammation. Suspicious clinical phenotypes include autoimmune encephalitis, atypical
  dementia, new-onset epilepsy and unexplained epileptic ...'
disable_comments: true
---
CONCLUSION: Our data suggest that KCNA2 autoimmunity is clinically heterogeneous. Future studies should determine whether KCNA2 autoantibodies are directly pathogenic or develop secondarily. Early immunotherapy should be considered, in particular if autoantibodies occur in CSF or if clinical or diagnostic findings suggest ongoing inflammation. Suspicious clinical phenotypes include autoimmune encephalitis, atypical dementia, new-onset epilepsy and unexplained epileptic ...